PVT1 is a Stress-responsive LncRNA That Drives Ovarian Cancer Metastasis and Chemoresistance

Overview

Journal Life Sci Alliance

Specialties Biochemistry
Biology
Cell Biology
Molecular Biology

Date 2022 Jul 12

PMID 35820706

Authors

Kevin Tabury

Mehri Monavarian

Eduardo Listik

Abigail K Shelton

Alex Seok Choi

Roel Quintens

Rebecca C Arend

Nadine Hempel

C Ryan Miller

Balazs Gyorrfy

Karthikeyan Mythreye

Affiliations

Soon will be listed here.

Abstract

Metastatic growth of ovarian cancer cells into the peritoneal cavity requires adaptation to various cellular stress factors to facilitate cell survival and growth. Here, we demonstrate the role of PVT1, one such stress induced long non-coding RNA, in ovarian cancer growth and metastasis. PVT1 is an amplified and overexpressed lncRNA in ovarian cancer with strong predictive value for survival and response to targeted therapeutics. We find that expression of PVT1 is regulated by tumor cells in response to cellular stress, particularly loss of cell-cell contacts and changes in matrix rigidity occurring in a YAP1-dependent manner. Induction of PVT1 promotes tumor cell survival, growth, and migration. Conversely, reducing PVT1 levels robustly abrogates metastatic behavior and tumor cell dissemination in cell lines and syngeneic transplantation models in vivo. We find that reducing PVT1 causes widespread changes in the transcriptome leading to alterations in cellular stress response and metabolic pathways including doxorubicin metabolism, which impacts chemosensitivity. Together, these findings implicate PVT1 as a promising therapeutic target to suppress metastasis and chemoresistance in ovarian cancer.

Citing Articles

Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications.

Basu S, Nadhan R, Dhanasekaran D Cancers (Basel). 2025; 17(3).

PMID: 39941838 PMC: 11815776. DOI: 10.3390/cancers17030472.

RNA-Independent Regulatory Functions of lncRNA in Complex Disease.

Kafida M, Karela M, Giakountis A Cancers (Basel). 2024; 16(15).

PMID: 39123456 PMC: 11311644. DOI: 10.3390/cancers16152728.

CRISPR du-HITI an attractive approach to targeting Long Noncoding RNA HCP5 as inhibitory factor for proliferation of ovarian cancer cell.

Moradi Z, Kazemi M, Jamshidi-Khalifelou R, Bahramnia V, Esfandmaz F, Rahnavard R Funct Integr Genomics. 2024; 24(2):61.

PMID: 38507114 DOI: 10.1007/s10142-024-01324-z.

Landscape of semi-extractable RNAs across five human cell lines.

Zeng C, Chujo T, Hirose T, Hamada M Nucleic Acids Res. 2023; 51(15):7820-7831.

PMID: 37463833 PMC: 10450185. DOI: 10.1093/nar/gkad567.

Application of natural polysaccharides and their novel dosage forms in gynecological cancers: therapeutic implications from the diversity potential of natural compounds.

Li Y, Zhang C, Feng L, Shen Q, Liu F, Jiang X Front Pharmacol. 2023; 14:1195104.

PMID: 37383719 PMC: 10293794. DOI: 10.3389/fphar.2023.1195104.

References

Varadaraj A, Patel P, Serrao A, Bandyopadhay T, Lee N, Jazaeri A . Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. Neoplasia. 2015; 17(11):826-38. PMC: 4681890. DOI: 10.1016/j.neo.2015.11.003. View

Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M . YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One. 2014; 9(3):e91770. PMC: 3951505. DOI: 10.1371/journal.pone.0091770. View

Han Y . Analysis of the role of the Hippo pathway in cancer. J Transl Med. 2019; 17(1):116. PMC: 6454697. DOI: 10.1186/s12967-019-1869-4. View

Patro R, Duggal G, Love M, Irizarry R, Kingsford C . Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017; 14(4):417-419. PMC: 5600148. DOI: 10.1038/nmeth.4197. View

Cho S, Xu J, Sun R, Mumbach M, Carter A, Chen Y . Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element. Cell. 2018; 173(6):1398-1412.e22. PMC: 5984165. DOI: 10.1016/j.cell.2018.03.068. View

Heibein A, Guo B, Sprowl J, MacLean D, Parissenti A . Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer. 2012; 12:381. PMC: 3495881. DOI: 10.1186/1471-2407-12-381. View

Jazaeri A, Bryant J, Park H, Li H, Dahiya N, Stoler M . Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia. 2011; 13(10):899-911. PMC: 3201567. DOI: 10.1593/neo.11138. View

Yi B, Kim T, Kim Y, Choi K . Alteration of epithelial-mesenchymal transition markers in human normal ovaries and neoplastic ovarian cancers. Int J Oncol. 2014; 46(1):272-80. DOI: 10.3892/ijo.2014.2695. View

Xu W, Mezencev R, Kim B, Wang L, McDonald J, Sulchek T . Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells. PLoS One. 2012; 7(10):e46609. PMC: 3464294. DOI: 10.1371/journal.pone.0046609. View

10.

Phelan C, Kuchenbaecker K, Tyrer J, Kar S, Lawrenson K, Winham S . Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017; 49(5):680-691. PMC: 5612337. DOI: 10.1038/ng.3826. View

11.

Sun L, Zhai R, Zhang L, Zhao S . MicroRNA-149 suppresses the proliferation and increases the sensitivity of ovarian cancer cells to cisplatin by targeting X-linked inhibitor of apoptosis. Oncol Lett. 2018; 15(5):7328-7334. PMC: 5920966. DOI: 10.3892/ol.2018.8240. View

12.

Yu F, Zhao B, Panupinthu N, Jewell J, Lian I, Wang L . Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012; 150(4):780-91. PMC: 3433174. DOI: 10.1016/j.cell.2012.06.037. View

13.

Cai Q, Yan L, Xu Y . Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells. Oncogene. 2014; 34(25):3315-24. PMC: 4333142. DOI: 10.1038/onc.2014.264. View

14.

Ding Y, Fang Q, Li Y, Wang Y . Amplification of lncRNA PVT1 promotes ovarian cancer proliferation by binding to miR-140. Mamm Genome. 2019; 30(7-8):217-225. DOI: 10.1007/s00335-019-09808-1. View

15.

Kumari A, Shonibare Z, Monavarian M, Arend R, Lee N, Inman G . TGFβ signaling networks in ovarian cancer progression and plasticity. Clin Exp Metastasis. 2021; 38(2):139-161. PMC: 7987693. DOI: 10.1007/s10585-021-10077-z. View

16.

DiStefano J, Davis B . Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma. Cancers (Basel). 2019; 11(4). PMC: 6521254. DOI: 10.3390/cancers11040486. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Iden M, Fye S, Li K, Chowdhury T, Ramchandran R, Rader J . The lncRNA PVT1 Contributes to the Cervical Cancer Phenotype and Associates with Poor Patient Prognosis. PLoS One. 2016; 11(5):e0156274. PMC: 4883781. DOI: 10.1371/journal.pone.0156274. View

19.

Lander E . Initial impact of the sequencing of the human genome. Nature. 2011; 470(7333):187-97. DOI: 10.1038/nature09792. View

20.

Zampetaki A, Albrecht A, Steinhofel K . Long Non-coding RNA Structure and Function: Is There a Link?. Front Physiol. 2018; 9:1201. PMC: 6117379. DOI: 10.3389/fphys.2018.01201. View